Medical research

Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer

Friday, April 3, 2020 - 9:46pm

MINNEAPOLIS, MN, April 03, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced it will pause enrollment in its ongoing clinical trial of SBP-101.

Key Points: 
  • MINNEAPOLIS, MN, April 03, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced it will pause enrollment in its ongoing clinical trial of SBP-101.
  • The COVID-19 pandemic has affected the conduct of clinical trials at our US and Australian sites.
  • Patients currently enrolled in the clinical trial will continue to be treated.
  • Sun BioPharmas development program is currently targeting pancreatic cancer; its initial product candidate is SBP-101 for the treatment of patients with metastatic pancreatic cancer.

2020 Cirrhosis Clinical Trials Overview by Trial Status & Phase, Sponsor Type, End Point Status, Region and Country - ResearchAndMarkets.com

Friday, April 3, 2020 - 6:02pm

The "Cirrhosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cirrhosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report, Cirrhosis Global Clinical Trials Review H1, 2020 provides an overview of Cirrhosis Clinical trials scenario.
  • The report provides top line data relating to the clinical trials on Cirrhosis.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update

Thursday, April 2, 2020 - 9:45pm

We are pleased to have worked with the Masonic Cancer Center, University of Minnesota to treat the first patient with FT596, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Key Points: 
  • We are pleased to have worked with the Masonic Cancer Center, University of Minnesota to treat the first patient with FT596, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.
  • The COVID-19 pandemic presents unprecedented challenges for clinical trial conduct worldwide, and we anticipate there will be delays across our studies.
  • We are also working closely with our clinical sites and principal investigators so that we are well positioned to accelerate clinical trial execution when pressures on the health system ease.
  • In response to the global COVID-19 pandemic, the Company is providing a business update on the conduct of its operations.

Accelerated Enrollment Solutions and Science 37 Collaborate to Provide Virtual Trial Access to Patients Globally

Thursday, April 2, 2020 - 2:00pm

These patients can instead participate in AES studies through Science 37s MetasiteTM, a hybrid clinical trial methodology that combines traditional site visits with remote trial capabilities, allowing patients located virtually anywhere to participate in a clinical trial.

Key Points: 
  • These patients can instead participate in AES studies through Science 37s MetasiteTM, a hybrid clinical trial methodology that combines traditional site visits with remote trial capabilities, allowing patients located virtually anywhere to participate in a clinical trial.
  • The collaboration also enables Science 37 to extend its investigator network by leveraging AES global research network.
  • Science 37 is already renowned for our ability to conduct fully decentralized trials in the United States, said David Coman, chief executive officer of Science 37.
  • Accelerated Enrollment Solutions is a business of PPD that offers sponsors and contract research organizations distinctive site conduct and patient access solutions.

RealTime Software Solutions keeping clinical research moving amid COVID-19 crisis

Thursday, April 2, 2020 - 10:00am

RealTime Software Solutions , a San Antonio based software company, is giving the industry a facelift that may forever change how research is conducted.

Key Points: 
  • RealTime Software Solutions , a San Antonio based software company, is giving the industry a facelift that may forever change how research is conducted.
  • Clinical trial monitors have historically visited research sites in person, collecting and monitoring crucial trial data.
  • RealTime has been at the forefront of clinical research technology, providing cutting-edge software to an industry that has been somewhat antiquated.
  • RealTime is a leader in advanced clinical research software with leading Clinical Trial Management Systems (CTMS), eSOURCE and eDOCS portals for completely paperless clinical trials.

APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19

Thursday, April 2, 2020 - 7:12am

The Phase II trial aims to treat 200 severely infected COVID-19 patients, and the first patients are expected to be dosed shortly.

Key Points: 
  • The Phase II trial aims to treat 200 severely infected COVID-19 patients, and the first patients are expected to be dosed shortly.
  • The randomized, double-blind Phase II trial will compare APN01 to placebo in up to 200 patients at 10 sites in Austria, Denmark and Germany.
  • The product candidate is currently in Phase II development by APEIRON Biologics for the treatment of PAH and ALI/ARDS, which is a significant cause of COVID-19-related mortalities.
  • APEIRONs APN01 (rhACE2) is starting a Phase II trial in Europe to treat COVID-19.

ERT Enables Clinical Trial Continuity through At-Home Respiratory Solutions

Wednesday, April 1, 2020 - 7:30pm

ERT's At-Home Respiratory Solutions enable clinical trial sponsors to continue developing new respiratory treatments while patient access to investigative sites is limited due to COVID-19 stay-at-home mandates.

Key Points: 
  • ERT's At-Home Respiratory Solutions enable clinical trial sponsors to continue developing new respiratory treatments while patient access to investigative sites is limited due to COVID-19 stay-at-home mandates.
  • The portable, battery-powered solutions provide clear, real-time quality feedback to obtain high-quality spirometry readings from patients and transfer data to the ERT Portal directly from patients' homes.
  • Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date.
  • By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly and with confidence.

Cirrhosis - Global Clinical Trials Review H1, 2020

Wednesday, April 1, 2020 - 4:45pm

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Cirrhosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 1, 2020 /PRNewswire/ -- The "Cirrhosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report, Cirrhosis Global Clinical Trials Review H1, 2020 provides an overview of Cirrhosis Clinical trials scenario.
  • The report provides top line data relating to the clinical trials on Cirrhosis.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Global Wounds Clinical Trials Review - H1, 2020 - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 4:37pm

The "Wounds Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wounds Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report, Wounds Global Clinical Trials Review, H1, 2020" provides an overview of Wounds Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Wounds.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Global Oral Cancer Clinical Trials Review - H1, 2020 - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 4:30pm

The "Oral Cancer Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oral Cancer Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report, Oral Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Oral Cancer Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Oral Cancer.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.